Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7198457 vs watchful waiting in ctDNA-positive resected Stage II/III colorectal cancer
2023-509516-28-00Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of autogene cevumeran in colon cancer, rectal cancer and colorectal cancer (CRC) (2 arms), sponsored by BioNTech SE. Primary endpoint: Disease-free survival. Started Feb 2021; status: completed.
02
Drugs
autogene cevumeran
03
Conditions
colon cancerrectal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509516-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509516-28-00.